Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

85.07 -0.94 (-1.09%)
Delayed Quote Updated: 12:46 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 484,327
Open 87.22
Bid (Size) 84.89 (100)
Ask (Size) 85.14 (100)
Prev. Close 86.01
Today's Range 81.95 - 88.31
52wk Range 63.23 - 130.00
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic... 
Via MarketBeat
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Performance

52-Week Range 34.6% below 52-week high
85.07
63.2352W Low 130.0052W High
1 Week 3.1% below 1-week high
77.781W Low 87.791W High

Mirum Pharmaceuticals, Inc. - common stock (MIRM) traded between $63.23 and $130.00 over the past 52 weeks and last traded at $85.07, 34.6% below its 52-week high. Over the past week it ranged between $77.78 and $87.79.

Past 12 Months
+4.5%
-13.4%
-28.5%
-11.8%
+9.0%
+17.9%
1W +$3.64
1M -$13.15
3M -$33.97
6M -$11.42
YTD +$7.00
1Y +$12.90

MIRM was +17.9% over the past year, -11.8% over six months, +9.0% year to date, +4.5% in the last week.

12 Months vs Market
MIRM
+17.9%
DIA
+12.4%
SPY
+17.4%
QQQ
+24.0%
IWM
+13.9%

Over the past 12 months MIRM returned +17.9% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +24.0% and IWM (Russell 2000) +13.9%.

Volume & Liquidity 0.69× 3-mo avg
Today 484,327 3-mo avg 705.8K
1W
990.4K
1M
896.3K
3M
705.8K
6M
851.3K
YTD
856.5K
1Y
808.3K

MIRM most recently traded 484,327 shares against a 3-month average daily volume of 705.8K.

More News

Read More
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study ↗
Via MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Via MarketBeat
News headline image
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharma: A Rare Disease Growth Story to Watch ↗
Via MarketBeat

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 85.07
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 10/12/26 12:46 PM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.26B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.